• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

www.nmpa.comJanuary 04, 2023

Tag: Ainuovirine , lamivudine

Recently, the innovative drug Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (trade name:复邦德) of Jiangsu Aidea Pharmaceutical Co., Ltd. is approved by China NMPA. This product is a compound medicine composed of Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate, which is indicated for the treatment of adult HIV-1 infected patients.

The marketing of this drug provides new treatment options for adult HIV-1 infected patients.

Previous:Mobocertinib succinate capsules approved for marketing with conditions

Next:China, New Zealand to further enhance science cooperation

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing - PharmaSources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Lamivudine API

Lamivudine API
Ibond® (Ainuovirine Tablets)

Ibond® (Ainuovirine Tablets)
Lamivudine Tablets (300mg, 150mg)

Lamivudine Tablets (300mg, 150mg)
lamivudine salicylate

lamivudine salicylate
Lamivudine USP Pharmaceutical Pharmaceutical API Antiviral drugs Nucleoside made in china

Lamivudine USP Pharmaceutical Pharmaceutical API Antiviral drugs Nucleoside made in china
Lamivudine

Lamivudine
'Lamivudine

'Lamivudine
lamivudine Cas 134678-17-4 from China

lamivudine Cas 134678-17-4 from China
  Lamivudine (3TC)

  Lamivudine (3TC)
Lamivudine

Lamivudine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service